RT @NatRevClinOncol: The FDA has converted the accelerated approval of pralsetinib for advanced-stage NSCLC with RET gene fusions to a regu…
So far, Altmetric has seen
166 X posts from 144 X users, with an upper bound of 2,523,113 followers.
4 followers
288 followers
Over the past 5 years, a surge in the rare-oncogene-driven lung cancers has challenged the boundaries of clinical grade diagnostic assays and profiling algorithms. It’s great to see the development of targeted treatments against rare molecular subtypes of
40,402 followers
The FDA has converted the accelerated approval of pralsetinib for advanced-stage NSCLC with RET gene fusions to a regular approval, based on updated data from the ARROW trial: https://t.co/d374hiX8PM. Another 'rare' NSCLC subtype successfully targeted: htt
327 followers
RT @HaradaGuilherme: 🚨“Rare” molecular subtypes of lung cancer: why should we care? 📝In this review out @NatRevClinOncol, we highlight tha…